Infectious events during the course of autoimmune diseases treated with rituximab: A retrospective study of 93 cases
Describe the occurring infections in patients treated with rituximab for an autoimmune disease. Retrospective and monocentric study of 93 adult patients treated with rituximab for autoimmune indications over a nine years period. Thirty-eight patients suffered from a total of 95 infections. Out of th...
Gespeichert in:
| Veröffentlicht in: | La revue de medecine interne 2017-03, Vol.38 (3), p.160-166 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | fre |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 166 |
|---|---|
| container_issue | 3 |
| container_start_page | 160 |
| container_title | La revue de medecine interne |
| container_volume | 38 |
| creator | Catroux, M Lauda-Maillen, M Pathe, M De Boisgrollier de Ruolz, A-C Cazenave-Roblot, F Roblot, P Souchaud-Debouverie, O |
| description | Describe the occurring infections in patients treated with rituximab for an autoimmune disease.
Retrospective and monocentric study of 93 adult patients treated with rituximab for autoimmune indications over a nine years period.
Thirty-eight patients suffered from a total of 95 infections. Out of them, 18 patients (19 %) had had at least an infectious episode triggering a hospital admission and/or intravenous treatment. The infections occurred mainly during the first year of the treatment (65 %) and if the courses are repeated (P=0.04). They were mainly pulmonary infections. Severe infections, recorded in 79 % of the cases, were mostly of bacterial origin (43 %) and viral (23 %). Two cases of pneumocystis pneumonia and one case of invasive pulmonary aspergillosis were also recorded. The notion of vaccination was present in less than half of the cases, and 39 % of the patients were already receiving a prophylactic treatment against pneumocystis pneumonia. Patients over the age of 65 years (40 %) had developed less infections (P |
| doi_str_mv | 10.1016/j.revmed.2016.09.010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1839115978</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1839115978</sourcerecordid><originalsourceid>FETCH-LOGICAL-p141t-17e38cf0dfa9a0540e97d645adeb20ef8fe6368b07eaa08fad0f850def6228623</originalsourceid><addsrcrecordid>eNo1kMtOwzAQRS0kREvhDxDykk3C2M7DYVdVPCohsYF15MRj6qpJih-F_g3fwpeRirIazejOkc4l5IpByoAVt-vU4a5DnfJxS6FKgcEJmbKykIlgnE_IufdrgPHMqjMy4aUUBefZlMRlb7ANdoie4g774KmOzvbvNKyQtkN0HulgqIphsF0Xe6TaelQePQ0OVUBNP21YUWdD_LKdau7onDoMbvDbA3iH1Ieo9wdIJX6-28PrBTk1auPx8jhn5O3h_nXxlDy_PC4X8-dkyzIWElaikK0BbVSlIM8Aq1IXWa40NhzQSIOFKGQDJSoF0igNRuag0YxysuBiRm7-uFs3fET0oe6sb3GzUT2OxjWTomIsr8Y6ZuT6GI3N2GS9daOM29f_VYlfjoBupA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1839115978</pqid></control><display><type>article</type><title>Infectious events during the course of autoimmune diseases treated with rituximab: A retrospective study of 93 cases</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Catroux, M ; Lauda-Maillen, M ; Pathe, M ; De Boisgrollier de Ruolz, A-C ; Cazenave-Roblot, F ; Roblot, P ; Souchaud-Debouverie, O</creator><creatorcontrib>Catroux, M ; Lauda-Maillen, M ; Pathe, M ; De Boisgrollier de Ruolz, A-C ; Cazenave-Roblot, F ; Roblot, P ; Souchaud-Debouverie, O</creatorcontrib><description>Describe the occurring infections in patients treated with rituximab for an autoimmune disease.
Retrospective and monocentric study of 93 adult patients treated with rituximab for autoimmune indications over a nine years period.
Thirty-eight patients suffered from a total of 95 infections. Out of them, 18 patients (19 %) had had at least an infectious episode triggering a hospital admission and/or intravenous treatment. The infections occurred mainly during the first year of the treatment (65 %) and if the courses are repeated (P=0.04). They were mainly pulmonary infections. Severe infections, recorded in 79 % of the cases, were mostly of bacterial origin (43 %) and viral (23 %). Two cases of pneumocystis pneumonia and one case of invasive pulmonary aspergillosis were also recorded. The notion of vaccination was present in less than half of the cases, and 39 % of the patients were already receiving a prophylactic treatment against pneumocystis pneumonia. Patients over the age of 65 years (40 %) had developed less infections (P<0.05). Eight of the initial 93 patients died, half of them because of infectious complications.
Infectious complications are frequent, become early and are potentially severe. Imputability to rituximab is not certain. However, this could lead to better codify rituximab prescriptions and take adapted and associated measures in order to facilitate infection prevention and, if an infection does occur, to treat it at the earliest stage possible. The age doesn't seem to be a risk factor.</description><identifier>EISSN: 1768-3122</identifier><identifier>DOI: 10.1016/j.revmed.2016.09.010</identifier><identifier>PMID: 27836224</identifier><language>fre</language><publisher>France</publisher><subject>Adult ; Aged ; Autoimmune Diseases - drug therapy ; Autoimmune Diseases - epidemiology ; Communicable Diseases - chemically induced ; Communicable Diseases - epidemiology ; Female ; France - epidemiology ; Humans ; Immunocompromised Host ; Male ; Middle Aged ; Retrospective Studies ; Rituximab - therapeutic use</subject><ispartof>La revue de medecine interne, 2017-03, Vol.38 (3), p.160-166</ispartof><rights>Copyright © 2016 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27836224$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Catroux, M</creatorcontrib><creatorcontrib>Lauda-Maillen, M</creatorcontrib><creatorcontrib>Pathe, M</creatorcontrib><creatorcontrib>De Boisgrollier de Ruolz, A-C</creatorcontrib><creatorcontrib>Cazenave-Roblot, F</creatorcontrib><creatorcontrib>Roblot, P</creatorcontrib><creatorcontrib>Souchaud-Debouverie, O</creatorcontrib><title>Infectious events during the course of autoimmune diseases treated with rituximab: A retrospective study of 93 cases</title><title>La revue de medecine interne</title><addtitle>Rev Med Interne</addtitle><description>Describe the occurring infections in patients treated with rituximab for an autoimmune disease.
Retrospective and monocentric study of 93 adult patients treated with rituximab for autoimmune indications over a nine years period.
Thirty-eight patients suffered from a total of 95 infections. Out of them, 18 patients (19 %) had had at least an infectious episode triggering a hospital admission and/or intravenous treatment. The infections occurred mainly during the first year of the treatment (65 %) and if the courses are repeated (P=0.04). They were mainly pulmonary infections. Severe infections, recorded in 79 % of the cases, were mostly of bacterial origin (43 %) and viral (23 %). Two cases of pneumocystis pneumonia and one case of invasive pulmonary aspergillosis were also recorded. The notion of vaccination was present in less than half of the cases, and 39 % of the patients were already receiving a prophylactic treatment against pneumocystis pneumonia. Patients over the age of 65 years (40 %) had developed less infections (P<0.05). Eight of the initial 93 patients died, half of them because of infectious complications.
Infectious complications are frequent, become early and are potentially severe. Imputability to rituximab is not certain. However, this could lead to better codify rituximab prescriptions and take adapted and associated measures in order to facilitate infection prevention and, if an infection does occur, to treat it at the earliest stage possible. The age doesn't seem to be a risk factor.</description><subject>Adult</subject><subject>Aged</subject><subject>Autoimmune Diseases - drug therapy</subject><subject>Autoimmune Diseases - epidemiology</subject><subject>Communicable Diseases - chemically induced</subject><subject>Communicable Diseases - epidemiology</subject><subject>Female</subject><subject>France - epidemiology</subject><subject>Humans</subject><subject>Immunocompromised Host</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Retrospective Studies</subject><subject>Rituximab - therapeutic use</subject><issn>1768-3122</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kMtOwzAQRS0kREvhDxDykk3C2M7DYVdVPCohsYF15MRj6qpJih-F_g3fwpeRirIazejOkc4l5IpByoAVt-vU4a5DnfJxS6FKgcEJmbKykIlgnE_IufdrgPHMqjMy4aUUBefZlMRlb7ANdoie4g774KmOzvbvNKyQtkN0HulgqIphsF0Xe6TaelQePQ0OVUBNP21YUWdD_LKdau7onDoMbvDbA3iH1Ieo9wdIJX6-28PrBTk1auPx8jhn5O3h_nXxlDy_PC4X8-dkyzIWElaikK0BbVSlIM8Aq1IXWa40NhzQSIOFKGQDJSoF0igNRuag0YxysuBiRm7-uFs3fET0oe6sb3GzUT2OxjWTomIsr8Y6ZuT6GI3N2GS9daOM29f_VYlfjoBupA</recordid><startdate>201703</startdate><enddate>201703</enddate><creator>Catroux, M</creator><creator>Lauda-Maillen, M</creator><creator>Pathe, M</creator><creator>De Boisgrollier de Ruolz, A-C</creator><creator>Cazenave-Roblot, F</creator><creator>Roblot, P</creator><creator>Souchaud-Debouverie, O</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201703</creationdate><title>Infectious events during the course of autoimmune diseases treated with rituximab: A retrospective study of 93 cases</title><author>Catroux, M ; Lauda-Maillen, M ; Pathe, M ; De Boisgrollier de Ruolz, A-C ; Cazenave-Roblot, F ; Roblot, P ; Souchaud-Debouverie, O</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p141t-17e38cf0dfa9a0540e97d645adeb20ef8fe6368b07eaa08fad0f850def6228623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>fre</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Autoimmune Diseases - drug therapy</topic><topic>Autoimmune Diseases - epidemiology</topic><topic>Communicable Diseases - chemically induced</topic><topic>Communicable Diseases - epidemiology</topic><topic>Female</topic><topic>France - epidemiology</topic><topic>Humans</topic><topic>Immunocompromised Host</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Retrospective Studies</topic><topic>Rituximab - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Catroux, M</creatorcontrib><creatorcontrib>Lauda-Maillen, M</creatorcontrib><creatorcontrib>Pathe, M</creatorcontrib><creatorcontrib>De Boisgrollier de Ruolz, A-C</creatorcontrib><creatorcontrib>Cazenave-Roblot, F</creatorcontrib><creatorcontrib>Roblot, P</creatorcontrib><creatorcontrib>Souchaud-Debouverie, O</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>La revue de medecine interne</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Catroux, M</au><au>Lauda-Maillen, M</au><au>Pathe, M</au><au>De Boisgrollier de Ruolz, A-C</au><au>Cazenave-Roblot, F</au><au>Roblot, P</au><au>Souchaud-Debouverie, O</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Infectious events during the course of autoimmune diseases treated with rituximab: A retrospective study of 93 cases</atitle><jtitle>La revue de medecine interne</jtitle><addtitle>Rev Med Interne</addtitle><date>2017-03</date><risdate>2017</risdate><volume>38</volume><issue>3</issue><spage>160</spage><epage>166</epage><pages>160-166</pages><eissn>1768-3122</eissn><abstract>Describe the occurring infections in patients treated with rituximab for an autoimmune disease.
Retrospective and monocentric study of 93 adult patients treated with rituximab for autoimmune indications over a nine years period.
Thirty-eight patients suffered from a total of 95 infections. Out of them, 18 patients (19 %) had had at least an infectious episode triggering a hospital admission and/or intravenous treatment. The infections occurred mainly during the first year of the treatment (65 %) and if the courses are repeated (P=0.04). They were mainly pulmonary infections. Severe infections, recorded in 79 % of the cases, were mostly of bacterial origin (43 %) and viral (23 %). Two cases of pneumocystis pneumonia and one case of invasive pulmonary aspergillosis were also recorded. The notion of vaccination was present in less than half of the cases, and 39 % of the patients were already receiving a prophylactic treatment against pneumocystis pneumonia. Patients over the age of 65 years (40 %) had developed less infections (P<0.05). Eight of the initial 93 patients died, half of them because of infectious complications.
Infectious complications are frequent, become early and are potentially severe. Imputability to rituximab is not certain. However, this could lead to better codify rituximab prescriptions and take adapted and associated measures in order to facilitate infection prevention and, if an infection does occur, to treat it at the earliest stage possible. The age doesn't seem to be a risk factor.</abstract><cop>France</cop><pmid>27836224</pmid><doi>10.1016/j.revmed.2016.09.010</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1768-3122 |
| ispartof | La revue de medecine interne, 2017-03, Vol.38 (3), p.160-166 |
| issn | 1768-3122 |
| language | fre |
| recordid | cdi_proquest_miscellaneous_1839115978 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adult Aged Autoimmune Diseases - drug therapy Autoimmune Diseases - epidemiology Communicable Diseases - chemically induced Communicable Diseases - epidemiology Female France - epidemiology Humans Immunocompromised Host Male Middle Aged Retrospective Studies Rituximab - therapeutic use |
| title | Infectious events during the course of autoimmune diseases treated with rituximab: A retrospective study of 93 cases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T21%3A56%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Infectious%20events%20during%20the%20course%20of%20autoimmune%20diseases%20treated%20with%20rituximab:%20A%20retrospective%20study%20of%2093%C2%A0cases&rft.jtitle=La%20revue%20de%20medecine%20interne&rft.au=Catroux,%20M&rft.date=2017-03&rft.volume=38&rft.issue=3&rft.spage=160&rft.epage=166&rft.pages=160-166&rft.eissn=1768-3122&rft_id=info:doi/10.1016/j.revmed.2016.09.010&rft_dat=%3Cproquest_pubme%3E1839115978%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1839115978&rft_id=info:pmid/27836224&rfr_iscdi=true |